DE68905516D1 - Hemmungsmittel des zellwachstums der glatten muskeln. - Google Patents

Hemmungsmittel des zellwachstums der glatten muskeln.

Info

Publication number
DE68905516D1
DE68905516D1 DE8989304369T DE68905516T DE68905516D1 DE 68905516 D1 DE68905516 D1 DE 68905516D1 DE 8989304369 T DE8989304369 T DE 8989304369T DE 68905516 T DE68905516 T DE 68905516T DE 68905516 D1 DE68905516 D1 DE 68905516D1
Authority
DE
Germany
Prior art keywords
inhibitors
cell growth
smooth muscles
muscles
smooth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8989304369T
Other languages
English (en)
Other versions
DE68905516T2 (de
Inventor
William E Benitz
Merton Bernfield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Application granted granted Critical
Publication of DE68905516D1 publication Critical patent/DE68905516D1/de
Publication of DE68905516T2 publication Critical patent/DE68905516T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE8989304369T 1988-05-03 1989-04-28 Hemmungsmittel des zellwachstums der glatten muskeln. Expired - Fee Related DE68905516T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/189,622 US4945086A (en) 1988-05-03 1988-05-03 Smooth muscle cell growth inhibitor

Publications (2)

Publication Number Publication Date
DE68905516D1 true DE68905516D1 (de) 1993-04-29
DE68905516T2 DE68905516T2 (de) 1993-08-12

Family

ID=22698106

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8989304369T Expired - Fee Related DE68905516T2 (de) 1988-05-03 1989-04-28 Hemmungsmittel des zellwachstums der glatten muskeln.

Country Status (4)

Country Link
US (1) US4945086A (de)
EP (1) EP0341006B1 (de)
JP (1) JPH0284402A (de)
DE (1) DE68905516T2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177020A (en) * 1985-03-28 1993-01-05 Hoechst Aktiengesellschaft Method for the immunological determination of heparan sulfate-proteoglycan and process for the preparation and purification of heparan sulfate-proteoglycan suitable for this purpose from tissues containing basal membrane
US5486599A (en) * 1989-03-29 1996-01-23 The Board Of Trustees Of The Leland Stanford Junior University Construction and use of synthetic constructs encoding syndecan
EP0493533A4 (en) * 1989-10-27 1992-10-28 Case Western Reserve University Inhibition of cell growth by keratan sulfate, chondroitin sulfate, dermatan sulfate and other glycans
ES2116331T3 (es) * 1991-01-15 1998-07-16 Biotie Therapies Oy Deteccion del contenido en sindecan en los materiales biologicos tales como tejidos o fluidos fisiologicos que indican transformaciones celulares malignas.
WO1992017506A1 (en) * 1991-03-29 1992-10-15 Glycomed, Inc. MODULATION OF tPA ACTIVITY BY HEPARIN FRAGMENTS
GB9111439D0 (en) * 1991-05-28 1991-07-17 Thrombosis Res Inst Inhibition of vascular smooth muscle cell proliferation
US5705178A (en) * 1991-05-31 1998-01-06 Gliatech, Inc. Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
WO1993005167A1 (en) * 1991-09-06 1993-03-18 Children's Medical Center Corporation Cell-type specific heparan sulfate proteoglycans and their uses
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease
US5665591A (en) * 1994-12-06 1997-09-09 Trustees Of Boston University Regulation of smooth muscle cell proliferation
US6262255B1 (en) 1995-04-05 2001-07-17 Biomm, Inc. Non-immunogenic, biocompatible macromolecular membrane compositions, and methods for making them
US6146847A (en) * 1996-11-01 2000-11-14 Genespan Corporation Stabilized transient gene expression
FI974321A0 (fi) 1997-11-25 1997-11-25 Jenny Ja Antti Wihurin Rahasto Multipel heparinglykosaminoglykan och en proteoglykan innehaollande dessa
DK2158923T3 (da) 1998-08-06 2013-03-25 Mountain View Pharmaceuticals Peg-uratoxidase-konjugater og anvendelse deraf
WO2001012675A1 (fr) * 1999-08-10 2001-02-22 Seikagaku Corporation Derives de glycosaminoglycane et leur utilisation
WO2001037853A2 (en) * 1999-11-23 2001-05-31 North Shore - Long Island Jewish Health System Methods and agents for the inhibition of smooth muscle cell proliferation
US7259152B2 (en) 2000-06-07 2007-08-21 Alfa Wasserman, Inc. Methods and compositions using sulodexide for the treatment of diabetic nephropathy
CZ2007700A3 (cs) 2005-04-11 2008-02-27 Savient Pharmaceuticals, Inc. Variantní forma urátoxidázy a její použití
US8188224B2 (en) 2005-04-11 2012-05-29 Savient Pharmaceuticals, Inc. Variant forms of urate oxidase and use thereof
US20080159976A1 (en) * 2005-04-11 2008-07-03 Jacob Hartman Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
ATE470701T1 (de) 2005-04-21 2010-06-15 Massachusetts Inst Technology Materialien und verfahren zur änderung einer immunreaktion auf exogene und endogene immunogene,einschliesslich genidentischer und nicht- genidentischer zellen, gewebe oder organe
JP2008545665A (ja) * 2005-05-23 2008-12-18 ユニベルシテ ドゥ ジュネーブ 高体温による処置のための注入可能な超常磁性ナノ粒子および高体温インプラントを形成するための使用
CN102743792B (zh) 2005-06-21 2014-09-24 夏尔再生医学公司 用于增强血管通路的方法和组合物
KR101288027B1 (ko) 2006-04-12 2013-07-22 새비언트 파마수티컬즈 인크. 양이온 계면활성제를 이용한 단백질 정제 방법
CN102803954A (zh) 2009-06-25 2012-11-28 萨文特制药公司 通过监测peg化尿酸酶治疗期间的血清尿酸预测输液反应风险和抗体介导的响应丧失的方法和试剂盒

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2281130A2 (fr) * 1974-08-08 1976-03-05 Thomas Andre Procede d'extraction et de traitement de glycoproteines, de mucopolysaccharides et de substances qui les accompagnent
US4446126A (en) * 1980-09-30 1984-05-01 Cutter Laboratories, Inc. Antithrombin-heparin complex and method for its production
GB2131294B (en) * 1982-11-30 1987-06-10 Univ Manchester Low molecular weight angiogenic factor
FR2538404B1 (de) * 1982-12-28 1985-08-23 Anic Spa
US4745098A (en) * 1984-02-24 1988-05-17 The Regents Of The University Of California Compositions and method for improving wound healing
US4760131A (en) * 1986-04-23 1988-07-26 Collagen Corporation Wound-healing composition

Also Published As

Publication number Publication date
EP0341006B1 (de) 1993-03-24
JPH0284402A (ja) 1990-03-26
EP0341006A3 (en) 1990-11-14
DE68905516T2 (de) 1993-08-12
US4945086A (en) 1990-07-31
EP0341006A2 (de) 1989-11-08

Similar Documents

Publication Publication Date Title
DE68905516T2 (de) Hemmungsmittel des zellwachstums der glatten muskeln.
ATE97652T1 (de) Peptidasehemmungsmittel.
FI891236A0 (fi) Doerrmanoevreringsanordning med laosmekanism foer hissar.
FI890657A0 (fi) Femringsystem med azacykliska ringsubstituenter.
FI880530A0 (fi) Med vaermare foersett bilsaete.
FI893295A (fi) Kommunikationssystem med en flervaegsantenn.
FI893379A (fi) Baerplan med laog resistans.
FI894556A0 (fi) Motorvagn foersedd med smidiga krypband.
FI880374A0 (fi) Skyddshuva eller -film med krympfoermaoga.
DE68907177D1 (de) Dosierungsform.
FI885342A0 (fi) Gasturbin med laenkinfaestning av en taetningsring i en ledskovelkrans.
FI893871A0 (fi) Vals med reglerbar boejning.
FI893248A (fi) Framstaellning av foereningar med bronkodilatorisk aktivitet.
DE68901509D1 (de) Hemmstoff der gefaessneubildung.
FI871257A0 (fi) Substituerade anilider av olje-, linol- och linolensyra saosom inhibitorer av acyl-coa:kolesterol-acyltransferas.
FI902534A0 (fi) Peptider med t-cellsuppressoraktivitet.
FI901509A0 (fi) Xylanasglykoprotein med laog molekylvikt.
FI880291A (fi) Varpvaevd enkeltrikao med lugg.
FI895989A0 (fi) Triazinoligomerestrar- och amider med en tetrametylpiperidylgrupp i aendstaellning.
ATA282688A (de) Peltonbecher
NO891715D0 (no) Ekspresjon av interferon-8 i metylotrofe gjaersorter.
DK69489A (da) Aspartattranscarbamylase-inhibitorer
FI894406A (fi) Med centerbord foersedd segelbaot.
FI890196A0 (fi) Limbar foervaringsficka med styrande egenskaper.
IT8822885A0 (it) Attivatore per osteoblasto

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee